#China #Chengdu #pharmaceutical #Keymed Biosciences #Kangyueda

Keymed Biosciences Achieves Remarkable Growth in H1 2026

On August 19, 2026, Keymed Biosciences, listed on HKEX under the stock number 02162, announced impressive interim results for the first half of 2026, which ended on June 30. The company, guided by a clear dual-engine strategy, showcased its excellent execution capabilities both domestically and internationally. Following the successful commercialization and securing of medical insurance coverage for its flagship product Kangyueda, Keymed's skilled in-house marketing team ramped up efforts, resulting in a dramatic increase in domestic revenue.

The performance surge was characterized by Kangyueda's revenue skyrocketing by an astonishing 132% to RMB393 million, which contributed significantly to the overall revenue of RMB617 million for the period. The impressive turnaround from a previous loss to a profit of RMB1,220 million was attributed to the efficient merger of NewCo with a multinational corporation (MNC) along with substantial enhancements in operational efficacy. Keymed's strong cash flow, backed by cash reserves amounting to approximately RMB3.24 billion, lays a solid foundation for ongoing growth and innovation worldwide.

Details of Dual-Wheel Growth Model

Keymed’s dual-engine growth model encompasses both robust domestic sales and thriving international collaborations. The company's commercialization team, bolstered to nearly 500 members, has been instrumental in its success, penetrating over 1,600 hospitals across 260 cities. The listing of Kangyueda in the National Essential Medicines List, effective September 1, 2026, is set to further amplify its availability in primary healthcare settings, thus expanding its market penetration.

In the international arena, Keymed's R&D remains in high demand, with collaborations yielding significant upfront payments and milestone revenues. The pharmaceutical landscape recognizes Keymed's innovative capabilities, which resonated through the strategic partnerships formed for its key pipelines.

Advancements in Key Drug Development

2026 has been a hallmark year for Keymed, marking the beginning of universal volume growth for Kangyueda under comprehensive medical insurance coverage. The company has pursued promising advancements in pipeline drug development, including Stapokibart, intended for treating moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN). Marketing applications for Stapokibart have been accepted, and clinical studies are currently ongoing, signifying Keymed's commitment to bringing innovative therapies to market.

The acquisition of Ouro Medicines, along with a strategic licensing agreement with AstraZeneca for CMG901/AZD0901, exemplifies the momentum Keymed has built. CMG901/AZD0901 is particularly noteworthy, having received FDA’s Fast Track and Orphan Drug designations and demonstrating definitive efficacy in treating gastric cancer, thus solidifying Keymed's position as a frontrunner in the pharmaceutical sector.

Pipeline Prospects and Market Strategy

Keymed continues to advance its clinical trials across various pipelines, including the promising compound CM512, a dual TSLP/IL-13 inhibitor. CM512 has shown significant efficacy in Phase II trials and is positioned to become a leading treatment option for autoimmune diseases. The continued investment in cutting-edge research and the development of therapeutics demonstrates Keymed’s ethos of innovation and adaptability in an ever-competitive market environment.

The substantial investments in R&D are supported by integrated platforms dedicating to various areas of immunology and oncology, highlighting Keymed's commitment to developing breakthrough therapies. With plans for further expansion in production capabilities, including new stainless-steel production lines due to come online, the company is poised for sustained growth.

Commitment to Quality and Accessibility

As it celebrates its tenth anniversary, Keymed Biosciences is steadfast in its mission to put patients first while accelerating the pace of bringing innovative solutions to treatment. The ongoing commitment to producing high-quality, affordable medicines reflects Keymed’s patient-centric philosophy and resolve to stimulate long-term value creation for shareholders.

In summary, Keymed Biosciences is navigating through 2026 on a strong trajectory of growth and innovation, with its dual-engine strategy and robust pipeline poised to deliver exceptional results in both domestic and international markets.